Clinical efficacy of dapagliflonzin combined with denosumab in the treatment of osteoporosis
Objective To investigate the clinical effect of Dapagliflonzin combined with Denosumab in the treatment of diabetes patients with osteoporosis,and to provide help for clinical treatment of patients with diabetes mellitus osteoporosis.Methods Forty patients with diabetes osteoporosis admitted to Zaozhuang Shanting District People's Hospital from January to June 2023 were selected and randomly divided into the conventional group,the dapagliflonzin group,the denosumab group and the combined treatment group,with 10 cases in each group.The conventional group was given conventional treatment.On the basis of conventional treatment,the dapagliflozin group was treated with dapagliflozin tablets,the denosumab group was treated with denosumab injection,and the combination treatment group was treated with dapagliflozin combined with denosumab.The bone density(BMD),bone metabolism and glucose metabolism related indicators among four groups of patients after 6 months of treatment were observed and compared.Results After 6 months of treatment,the BMD of lumbar vertebrae L1-4,femoral neck and total hip in the denosumab group and the combination treatment group were higher than those in the conventional group and dapagliflonzin group;the β-CTX and OC in the denosumab group and the combination treatment group were significantly lower than those in the conventional group and dapagliflozin group,while the 25(OH)D were significantly higher than those in the conventional group and dapagliflozin group;the FBG,2hPBG and HbAlc of the dapagliflozin group and combination treatment group were significantly lower than those of the conventional group;the FBG,2hPBG and HbAlc of the combination treatment group were significantly lower than those of the dapagliflozin group and denosumab group,and the differences were statistically significant(P＜0.05).Conclusion The combination application of dapagliflonzin and denosumab could regulate and control the blood glucose and HbAlc in patients with diabetes osteoporosis,and could improve bone metabolism,increase the BMD of patients,reduce the probability of fracture,and alleviate the pain of patients.It had clinical application value and promotion significance.
NETL
NSTL
万方数据
